<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6416">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01742403</url>
  </required_header>
  <id_info>
    <org_study_id>12-NSCCRO-P001</org_study_id>
    <nct_id>NCT01742403</nct_id>
  </id_info>
  <brief_title>Continuous Monitoring of Prostate Position During Radiotherapy</brief_title>
  <acronym>KIM Gating</acronym>
  <official_title>Phase I Feasibility Study of Prostate Cancer Radiotherapy Gating Using kV Intrafraction Monitoring (KIM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal North Shore Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal North Shore Hospital</source>
  <oversight_info>
    <authority>Australia: Human Research Ethics Committee</authority>
    <authority>Australia: National Health and Medical Research Council</authority>
    <authority>Australia: Therapeutic Goods Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is investigating measurement of prostate motion during radiotherapy using the
      implanted gold markers. If motion is greater than 3mm then the beam will be stopped and
      position corrected (gating).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Technique will be determined as feasible if 90% of treatment fractions are successfully segmented in real time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time for procedure</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of time taken to perform KIM gating to guide future department resource questions.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy gating using kV intrafraction monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Prostate cancer radiotherapy gating using kV intrafraction monitoring (KIM)</intervention_name>
    <arm_group_label>Radiotherapy gating using kV intrafraction monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing definitive external beam radiotherapy;

          -  Histological proven prostate adenocarcinoma

          -  Prostate Specific Antigen (PSA),within 3 months prior to enrolment

          -  Patient must be able to have gold fiducial markers placed in the prostate (if on
             anticoagulants, must be approved for procedure by Cardiologist)

          -  ECOG 0-2

          -  Ability to understand and willingness to sign informed consent form.

        Exclusion Criteria:

          -  Lymph node irradiation

          -  Altered fractionation

          -  Artificial hip(s)

          -  Patient Dimensions &lt;50cm

          -  Overlapping fiducials (for segmentation)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Eade, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal North Shore Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas N Eade, MBBS</last_name>
    <phone>+61294631319</phone>
    <email>TEade@nsccahs.health.nsw.gov.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeremy Booth, PhD</last_name>
    <phone>+61294631320</phone>
    <email>JBooth@nsccahs.health.nsw.gov.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Northern Sydney Cancer Centre</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas N Eade, MBBS</last_name>
      <phone>+61294631315</phone>
      <email>TEade@nsccahs.health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Thomas N Eade, RANZCR I &amp; II</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 3, 2013</lastchanged_date>
  <firstreceived_date>December 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal North Shore Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Thomas Eade</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>IGRT</keyword>
  <keyword>VMAT</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
